PMID- 21278436
OWN - NLM
STAT- MEDLINE
DCOM- 20110624
LR  - 20220321
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Linking)
VI  - 16 Suppl 1
DP  - 2011
TI  - Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.
PG  - 12-9
LID - 10.1634/theoncologist.2011-S1-12 [doi]
AB  - The phosphoinositide-3 kinase (PI3K) pathway has been identified as an important 
      target in breast cancer research for a number of years, but is new to most 
      clinicians responsible for the daily challenges of breast cancer management. In 
      fact, the PI3K pathway is probably one of the most important pathways in cancer 
      metabolism and growth. Mutations in the PI3K pathway are frequent in breast 
      cancer, causing resistance to human epidermal growth factor receptor 2-targeted 
      agents and, possibly, to hormonal agents as well. Available agents that affect 
      the PI3K pathway include monoclonal antibodies and tyrosine kinase inhibitors, as 
      well as PI3K inhibitors, Akt inhibitors, rapamycin analogs, and mammalian target 
      of rapamycin (mTOR) catalytic inhibitors. Multiple PI3K inhibitors are currently 
      under development, including pure PI3K inhibitors, compounds that block both PI3K 
      and mTOR (dual inhibitors), pure catalytic mTOR inhibitors, and inhibitors that 
      block Akt. It is likely that these agents will have to be given in combination 
      with other signal inhibitors because anti-mTOR agents and PI3K inhibitors may 
      result in the activation of compensatory feedback loops that would in turn result 
      in decreased efficacy. This article reviews current data related to the PI3K 
      pathway, its role in breast cancer, the frequency with which PI3K is aberrant in 
      breast cancer, and the potential clinical implications of using agents that 
      target the PI3K pathway.
FAU - Baselga, Jose
AU  - Baselga J
AD  - Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, 
      Boston, Massachusetts 02114, USA. jbaselga@partners.org
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
SB  - IM
MH  - Breast Neoplasms/*drug therapy/*enzymology/genetics
MH  - Female
MH  - Humans
MH  - Molecular Targeted Therapy/methods
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - *Phosphoinositide-3 Kinase Inhibitors
MH  - Signal Transduction/drug effects
EDAT- 2011/02/10 06:00
MHDA- 2011/06/28 06:00
CRDT- 2011/02/01 06:00
PHST- 2011/02/01 06:00 [entrez]
PHST- 2011/02/10 06:00 [pubmed]
PHST- 2011/06/28 06:00 [medline]
AID - 16/suppl_1/12 [pii]
AID - 10.1634/theoncologist.2011-S1-12 [doi]
PST - ppublish
SO  - Oncologist. 2011;16 Suppl 1:12-9. doi: 10.1634/theoncologist.2011-S1-12.